Karabiber, E. Et Al. 2017. Hyperamylasemia among patients treated with omalizumab. Congress of the European-Academy-of-Allergy-and-Clinical-Immunology , (Helsinki, Finland), 323-324.

Karabiber, E., Aktas, O. O., Ozdemir, E., Celebioglu, E., Sahiner, U. M., Karakaya, G., ... Kalyoncu, A. F.(2017). Hyperamylasemia among patients treated with omalizumab . Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (pp.323-324). Helsinki, Finland

Karabiber, E. Et Al. "Hyperamylasemia among patients treated with omalizumab," Congress of the European-Academy-of-Allergy-and-Clinical-Immunology, Helsinki, Finland, 2017

Karabiber, E. Et Al. "Hyperamylasemia among patients treated with omalizumab." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology , Helsinki, Finland, pp.323-324, 2017

Karabiber, E. Et Al. (2017) . "Hyperamylasemia among patients treated with omalizumab." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology , Helsinki, Finland, pp.323-324.

@conferencepaper{conferencepaper, author={E. Karabiber Et Al. }, title={Hyperamylasemia among patients treated with omalizumab}, congress name={Congress of the European-Academy-of-Allergy-and-Clinical-Immunology}, city={Helsinki}, country={Finland}, year={2017}, pages={323-324} }